HLB is taking control of changes of the future in various business fields, with
constant efforts and passion.
Elevar therapeutics and Neopharma establish a JV for the commercialization of Rivoceranib
Elevar Therapeutics and Abu Dhabi-based Neopharma have entered into an agreement to establish a joint venture in the United Arab Emirates. The 50:50 venture is planned to undertake a broad range of development and commercialization activities for Rivoceranib in the Middle East, North Africa, and India.
“We are excited to kick off this partnership with Neopharma,” said Alex Kim, Elevar Therapeutics’ CEO, “the JV will benefit greatly from the Neopharma’s vast sales network in the MENA region, fully integrated manufacturing, and broad development expertise.”